1. Pink Sheet
  2. >>Legal & IP

FTC Suit Kills Sanofi/Maze Licensing Deal; Will It Doom The Pompe Candidate?

 
• By Nielsen Hobbs

Faced with a lawsuit asserting it had acquired an asset because it was a potential threat, Sanofi bows out of agreement to develop Maze’s GYS1 inhibitor. A test for FTC’s competition theory will be whether MZE001 eventually makes it to the market through other means.

Stop-sign-and-stop-light
The Sanofi/Maze deal will not be moving forward • Source: Shutterstock

The US Federal Trade Commission’s more muscular antitrust enforcement under the Biden administration notched another win on 11 December when Sanofi terminated its development agreement with Maze Therapeutics for the Pompe disease candidate MZE001.

FTC had authorized a lawsuit challenging Sanofi’s deal with Maze on grounds that it would “eliminate a nascent competitor poised...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

US FDA Will Not Pull Teva And MSN Hetlioz ANDAs, Rejects Vanda Citizen Petitions

 
• By Dean Rudge

The FDA concluded that generic tasimelteon products held by Teva and MSN Labs meet all statutory bioequivalence requirements and there was no “mistake” or untrue statement in the original ANDA approvals.

EU Fines Alchem Over Buscopan API Cartel

 
• By Dave Wallace

After pursuing Alchem International for breaches of EU antitrust rules – relating to a cartel over the SNBB pharmaceutical ingredient used in Buscopan and its generics – the European Commission has now hit the firm with a €489,000 fine.

Clinical Trial Diversity Action Plan Guidance Must Return To US FDA Website, Court Says

 
• By Sue Sutter

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.

Lawyers Weigh In On ‘Sunshine’ Clause In EU Pharma Reform Package

 
• By Eliza Slawther

The Council of the EU has not taken forward a proposal from the European Parliament that would require companies to disclose the transfers of value they make to health care professionals and health care organizations – lawyers weigh in on the diverging proposals.

More from Pink Sheet